Eevia Health Plc receives approval for its top bilberry extract from an old customer and the first new order in 18 months of c. 572 KSEK (50 KEUR)
Eevia Health Plc ("Eevia" or "The Company") has received approval of a second product from an old US nutraceutical customer and received a new 50 KEUR (572 KSEK) sales order. The US nutraceutical brand owner was between 2021 and 2023 Eevia's largest customer but stopped ordering in mid-2023 due to overstocking. The order is the customer's first new sales order in 18 months.
The US customer is one of the largest brand owners in the world. It specializes in producing natural health products, particularly dietary supplements. The highly recognized global brand owner offers a wide range of vitamins, minerals, herbs, and other products to promote healthy living, including immune support, digestive health, and overall well-being. Eevia sold this customer significant volumes of Feno-Sambucus 14, an elderberry extract, in the period 2021 to 2023. However, during the COVID crisis, the company overstocked and consequently halted procurement of new material in mid-2023. Eevia’s elderberry sales are expected to resume to this customer by the end of 2025.
Eevia underwent a meticulous qualification process for its Feno-Myrtillus® 36 product during the fall of 2024, and recently, the customer approved the product. Following this qualification, a first new order was received for Feno-Myrtillus® 36, a bilberry extract standardized for anthocyanins, with a sales value to Eevia of c. 50 KEUR. Eevia has the product in stock, which is helpful for cash flow, and will ship immediately. Eevia services this customer without using a distributor. Eevia was selected due to its high quality and product authenticity. The expected annual value from this product is c. 300 KEUR.
“We welcome the approval of our bilberry extract and this new first sales order and look forward to developing the business with this great customer,“ says Anna-Maija Vanhatalo, Eevia’s Customer Service Manager.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.
Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
As a pioneering company, Eevia is developing biomaterials that may have a dramatic impact on human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.